Leukemia Research
Volume 26, Issue 8 , Pages 745-755 , August 2002

Human B-cell lymphoma cell lines are highly sensitive to apoptosis induced by all-trans retinoic acid and interferon-γ

  • Nozomi Niitsu

      Affiliations

    • Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, 1-15-1 Kitasato, Sagamihara-shi, Kanagawa 228-8555, Japan
    • Saitama Cancer Center and Research Institute, Saitama, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-42-778-8111; fax: +81-42-778-9847
    • ,
  • Masaaki Higashihara

      Affiliations

    • Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, 1-15-1 Kitasato, Sagamihara-shi, Kanagawa 228-8555, Japan
    • ,
  • Yoshio Honma

      Affiliations

    • Saitama Cancer Center and Research Institute, Saitama, Japan

Received 11 September 2001 ,Accepted 4 December 2001.

References 

  1. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al.  A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–1392
  2. Bastion Y, Berger F, Bryon PA, Felman P, Ffrench M, Coiffier B. Follicular lymphoma: assessment of prognostic factors in 127 patients followed for 10 years. Annu. Oncol. 1991;2:123–134
  3. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al.  Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol. 1999;17:268–276
  4. Shipp MA. A predictive model for aggressive non-Hodgkin’s lymphomas: The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N. Engl. J. Med. 1993;329:987–994
  5. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N. Engl. J. Med. 1993;328:1002–1006
  6. Miller TP, Dana BW, Weick JK, Jones SE, Coltman CA, Dahlberg S, et al.  Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin’s lymphomas. Semin. Hematol. 1998;25:17–22
  7. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, et al.  High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N. Engl. J. Med. 1997;336:1290–1297
  8. Warrell RP. Applications for retinoids in cancer therapy. Semin. Hematol. 1994;31:1–13
  9. Blomhoff HK, Smeland EB, Erikstein B, Rasmussen AM, Skrede B, Skjonsberg C, et al.  Vitamin A is a key regulator for cell growth, cytokine production, and differentiation in normal B-cells. J. Biol. Chem. 1992;267:23988–23992
  10. Honma Y, Takenaga K, Kasukabe T, Hozumi M. Induction of differentiation of cultured human promyelocytic leukemia cells by retinoids. Biochem. Biophys. Res. Commun. 1980;95:507–512
  11. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72:567–572
  12. Chambon P. The retinoid signaling pathway: molecular and genetic analyses. Semin. Cell Biol. 1994;5:115–125
  13. Buschle M, Campana D, Carding SR, Richard C, Hoffbrand AV, Brenner MK. Interferon gamma inhibits apoptotic cell death in B-cell chronic lymphocytic leukemia. J. Exp. Med. 1993;177:213–218
  14. Darnell JE. STATs and gene regulation. Science. 1997;277:1630–1635
  15. Decker T, Kovarik P, Meinke A. GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression. J. Interf. Cytokine Res. 1997;17:121–134
  16. Iijima T, Endo Y, Tsuji M, Kawachi E, Kagechika H, Shudo K. Dicarba-closo-dodecaboranes as a pharmacophore. Retinoidal antagonists and potential agonists. Chem. Pharm. Bull. 1999;47:398–404
  17. Lok MS, Koshiba H, Han T, Abe S, Minowada J, Sandberg AA. Establishment and characterization of human B lymphocytic lymphoma cell lines (BALM-3, BALM-4, and BALM-5): intraclonal variation in the B-cell differentiation stage. Int. J. Cancer. 1979;24:572–578
  18. Epstein AL, Herman MM, Kim H, Dorfman RF, Path MRC, Kaplan HS. Biology of the human malignant lymphomas. Part III. Intracranial heterotransplantation in the nude, athymic mouse. Cancer. 1976;37:2158–2176
  19. Nilsson K, Sundstrom C. Establishment and characteristics of two unique cell lines from patients with lymphosarcoma. Int. J. Cancer. 1974;13:808–823
  20. Nilsson K, Klareskog L, Ralph P, Sundstrom C, Zech L. Phenotypic and cytogenetic characteristics of a new Epstein-Barr virus negative cell line (SKW4) derived from a B-cell lymphoma. Hematol. Oncol. 1983;1:277–295
  21. Minowada J, Oshimura M, Tsubota T, Higby DJ, Sandberg AA. Cytogenetic and immunoglobulin markers of human leukemic B-cell lines. Cancer Res. 1977;37:3096–3099
  22. Niitsu N, Yamaguchi Y, Umeda M, Honma Y. Human monocytoid leukemia cells are highly sensitive to apoptosis induced by 2′-deoxycoformycin and 2′-deoxyadenosine: association with dATP-dependent activation of caspase-3. Blood. 1998;92:3368–3375
  23. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, et al.  A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992;356:768–774
  24. Niitsu N, Masanori U, Honma Y. Induction of differentiation of human myeloid leukemia cells by 2′-deoxycoformycin in combination with 2′-deoxyadenosine. Biochem. Biophys. Res. Commun. 1997;238:100–106
  25. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction. Anal. Biochem. 1987;162:156–159
  26. Petkovich M, Brand NJ, Krust A, Chambon P. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature. 1987;330:444–450
  27. Mangelsdorf DJ, Borgmeyer U, Heyman RA, Zhou JY, Ong ES, Oro AE, et al.  Characterization of three RXR genes that mediate the action of 9-cis-retinoic acid. Genes Dev. 1992;6:329–344
  28. Heyman RA, Mangelsdorf DJ, Dyck JA, Stein RB, Eichele G, Evans RM. 9-Cis-retinoic acid is a high affinity ligand for the retinoid X receptor. Cell. 1992;68:397–406
  29. Kagechika H, Kawachi E, Hashimoto Y, Himi T, Shudo K. Retinobenzoic acids. Part 1. Structure–activity relationships of aromatic amides with retinoidal activity. J. Med. Chem. 1988;31:2182–2192
  30. Apfel CM, Kamber M, Klaus M, Mohr P, Keidel S, LeMotte PK. Enhancement of HL-60 differentiation by a new class of retinoids with selective activity on retinoid X receptor. J. Biol. Chem. 1995;270:30765–30772
  31. Fernandes-Alnemri T, Litwack G, Alnemri ES. CPP32, a novel human apoptotic protein with homologue to Caenorhabditis elegans cell death protein ced-3 and mammalian interleukin-1β-converting enzyme. J. Biol. Chem. 1994;269:30761–30764
  32. Sen GC, Ransohoff RM. Interferon-induced anti-viral actions and their regulations. Adv. Virus Res. 1993;42:57–102
  33. Taniguchi T, Harada H, Lamphier M. Regulation of the interferon system and cell growth by the IRF transcription factors. J. Cancer Res. Clin. Oncol. 1995;121:516–520
  34. Cheng AL, Su I, Chen C, Tien H, Lay J, Chen B, et al.  Use of retinoic acids in the treatment of peripheral T-cell lymphoma: a pilot study. J. Clin. Oncol. 1994;12:1185–1192
  35. Sundaresan A, Claypool K, Mehta K, Lopez-Berestein G, Cabanillas F, Ford RJ. Retinoid-mediated inhibition of cell growth with stimulation of apoptosis in aggressive B-cell lymphomas. Cell Growth Differ. 1997;8:1071–1082
  36. Darnell J. STATs and gene regulation. Science. 1997;277:1630–1635
  37. Schindler C. Cytokine signal transduction. Receptor. 1995;5:51–62
  38. Stark GR, Kerr IM, William BRG, Silverman RH, Schreiber RD. How cells respond to interferons. Annu. Rev. Biochem. 1998;67:227–264
  39. Zaki M, Douglas R, Patten N, Bachinsky M, Lamb R, Nowell P, et al.  Disruption of the IFN-γ cytokine network in chronic lymphocytic leukemia contributes to resistance of leukemic B-cells to apoptosis. Leuk. Res. 2000;24:611–621
  40. Horikoshi T, Onodera H, Eguchi H, Hanada N, Fukuzawa K, Takahashi M, et al.  A patient with plaque-stage mycosis fungoides has successfully been treated with long-term administration of IFN-gamma and has been in complete remission for more than 6 years. Br. J. Dermatol. 1996;134:130–133
  41. Lippman SM, Glisson BS, Kavanagh JJ, Lotan R, Hong WK, Paredes-Espinoza M, et al.  Retinoic acid and interferon combination studies in human cancer. Eur. J. Cancer. 1993;29A:9–13
  42. Lippman SM, Lotan R, Schleuniger U. Retinoid–interferon therapy of solid tumors. Int. J. Cancer. 1997;70:481–483
  43. Kumar R, Korutla L. Growth inhibition of human acute promyelocytic leukemia NB4 cells by interferons and all-trans retinoic acid: trans-modulation of inducible gene expression pathways. Anticancer Res. 1995;15:353–360
  44. Bollag W. Retinoids and interferon: a new promising combination?. Br. J. Haematol. 1991;79:87–91
  45. Weihua X, Kolla V, Kalvakolanu DV. Modulation of interferon action by retinoids. Induction of murine STAT-1 gene expression by retinoic acid. J. Biol. Chem. 1997;272:9741–9748
  46. Matikainen S, Ronni T, Lehtonen A, Sareneva T, Melen K, Nordling S. Retinoic acid induces signaltransducer and activator of transcription (STAT) 1, STAT 2, and p48 expression in myeloid leukemia cells and enhances their responsiveness to interferons. Cell Growth Diff 1997;687–98.
  47. Maloney DG, Grillo-Lopez AJ, White CA, Grillo-Lopez AJ, White CA, Bodkin D, et al.  IDEC-C2B8 (Rituximab) antibody CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997;90:2188–2195
  48. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al.  Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclocal antibody and CHOP chemotherapy. J. Clin. Oncol. 1999;16:268–276

PII: S0145-2126(01)00202-8

Leukemia Research
Volume 26, Issue 8 , Pages 745-755 , August 2002

Article Tools

* Image Usage & Resolution